12/04/2025 13:00
Parse Biosciences Launches Evercode Whole Blood Fixation

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings ...

12/04/2025 13:00
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™

Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/Darien Bi...

12/04/2025 13:00
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are...

11/20/2025 08:56
MVNO Europe calls on the European Commission to enable a true Single Market for mobile connectivity and Internet of Things (IoT) through the Digital Networks Act

The upcoming legislative proposal for a Digital Networks Act (DNA) marks a defining moment for the European Union to build a true Single Market for electronic communications based on openness, competition and innovation. MVNO Europe believes the upcoming DNA should build on the achievements of the existing EU regulatory framework by strengthening competition among diverse providers. This competition drives innovation and delivers tangible benefits for European consumers and businesses. Ensuri...

11/20/2025 09:00
euNetworks Appoints Nick Walden as Chief Revenue Officer

euNetworks has today announced the appointment of Nick Walden as Chief Revenue Officer, effective 02 December 2025. Nick will be based in London and will drive all facets of euNetworks’ sales and commercial strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120550034/en/Nick Walden - CRO of euNetworks Nick joins euNetworks following 30+ years in the Telecommunications industry, most recently having led the Global Sales func...